News and Events
Large Prospective Trial Validates Detection of AR-V7 Biomarker Using Epic Sciences’ Platform to Predict Treatment Outcomes for Patients with Advanced Prostate Cancer
New data from the PROPHECY trial, published in the Journal of Clinical Oncology, demonstrate that detection of AR-V7 in circulating tumor cells (CTCs) in blood is predictive of whether men with mCRPC have become resistant to androgen-receptor signaling (ARS) inhibitors and have a low chance of benefit from further ARS therapy.
Epic Sciences to Present at ASCO-GU 2019 New Data Demonstrating Utility of Liquid Biopsy to Optimize Drug Development
Epic Sciences, Inc. (Epic) announced today the presentation of four posters at the 2019 American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO-GU), held in San Francisco on February 14-16, 2019.
Epic Sciences to Present Data at SABCS 2018
Epic Sciences, Inc. (Epic) announced today that they will be presenting new data on inter- and intra-patient phenotypic heterogeneity and the use of HER2 and AR expression in metastatic breast cancer circulating tumor cells at the 2018 San Antonio Breast Cancer Symposium (SABCS) from December 4 - 8 in San Antonio, TX.
Epic Sciences Joins Forces with Canadian Consortium of Investigators to Predict Late Recurrence of Metastatic Breast Cancer
Epic Sciences is collaborating with four major breast cancer centers on a clinical trial to determine if Epic’s blood test can be used to predict which women, who have already been treated for localized breast cancer, are at risk of late recurrence of metastatic breast cancer.
Medicare Establishes Final Local Coverage Determination (LCD) for Use of the Oncotype DX® AR-V7 Nucleus Detect™ Test in Patients with Metastatic Castrate Resistant Prostate Cancer, Effective December 10
Medicare coverage supports clinical utility of the Oncotype DX AR-V7 Nucleus Detect test, providing 25,000 Medicare patients with coverage.
Calendar of Events
ASCO GU 2019
ASCO Genitourinary Cancer Symposiums Annual Meeting in San Francisco, CA from February 14 - 16, 2019.
Society for Immunotherapy of Cancer 2018 Annual Meeting in Washington, D.C. from November 7 - 11, 2018.
In the News
AR-V7 status predicts abiraterone, enzalutamide response in mCRPC
The PROPHECY study represents a multicenter effort that provides prospective, blinded clinical validation around such an approach and suggests that both the JHU CTC AR-V7 mRNA assay and the Epic CTC nuclear-specific AR-V7 protein assay provide clinical utility around the anticipated outcomes with therapy.
Test Predicts Resistance to Hormonal Therapy in Prostate Cancer - Validation study confirms assist in decision-making
A blood test that measures the spliced variant of an androgen receptor called AR-V7 in circulating tumor cells successfully predicted resistance to commonly used hormonal therapy agents in advanced prostate cancer, a validation study confirmed.
Blood Tests Predict Effectiveness of Hormonal Therapies
A multi-institutional group of clinical researchers, led by the Duke Cancer Institute’s Andrew Armstrong, MD, McS, FACP, published a new report this month in the Journal of Clinical Oncology, that describes results from the PROPHECY study, which prospectively compared two blood tests to assess how well they predicted the effectiveness of hormonal therapy in men with metastatic prostate cancer.
Blood Test Study Meets Goal, Validates Epic’s Prostate Cancer Target
Epic Sciences has commercialized a blood test that can predict how likely a patient with late-stage prostate cancer treated with hormones is likely to respond to an additional course of such therapy. Now, the San Diego-based company has additional data that it says supports use of its tests to determine when not to use hormone therapy.
CTC AR-V7 Validated as Predictive Marker of Resistance to AR-Directed Therapy in mCRPC
Nuclear-localized androgen receptor splice variant 7 (AR-V7) protein in circulating tumor cells (CTCs) is a predictive marker of shorter progression-free and overall survival (OS) with antiandrogen therapy in patients with metastatic castration-resistant prostate cancer (mCRPC), according to results from the phase III PROPHECY trial that were published in the Journal of Clinical Oncology.
Every time Epic’s AR-V7 test is administered the healthcare system saves about $15,000 per year of life extended. In other words approximately $7,000 to $9,000 per patient tested.
Of the roughly 30 million cells in a typical blood sample, about 5 are cancer cells on their way to form tumors elsewhere in the body. Modern cancer diagnostics technology can't see them.
We spend about $100 billion a year on cancer drugs. But because we’re not matching the right drug to the right patient and their disease in a personalized way, about 3/4ths of that drug spend is wasted.
The Epic approach answers a critical question for a doctor: When is a patient resistant? By answering that question accurately and precisely we increase patient life and save the system money at the same time.
Today, Epic Sciences is embedded in clinical trials with 48 leading producers of oncology drugs and 35 of the top academic cancer hospitals.
It takes only 7 minutes to acquire an entire image of 6 million stained cells on a 1 x 3 slide. Then that image, which is about 20GB of data, gets sent up to the cloud where the algorithms run and find the rare events in about 2 more minutes.